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1Sir — Viral particles and reverse transcriptase activity have been found
in cell culture from patients with multiple sclerosis (MS).1,2 Since the ﬁrst
description of MS associated retrovirus (MSRV) in 1989,1 this has been
investigated as a possible cause of MS.3 A pathogenic link to gliotoxi-
city has been suggested.4 Indeed, a recent study found MSRV in the
plasma of a signiﬁcantly higher proportion (39/39, 100%) of MS patients
compared to patients with other inﬂammatory neurological diseases (7/10,
63.6%, p=0.004) or to healthy blood donors (5/39, 12.8%) from Sardinia,
where epidemiological studies revealed an intriguing increase in MS over
the past decades.5 Moreover, a retrospective study showed that detection
of MRSV in CSF had a predictive value for MS patients at disease onset.6
It remains unclear whether the presence of MSRV merely represents an
epiphenomenon in MS patients or is of aetiological importance.
This study aimed to investigate ﬁrstly whether circulating MSRV could
be detected in patients with acute optic neuritis as opposed to clinical MS.5
Secondly, we hypothesised that those patients with MSRV viraemia may
have a higher risk of developing MS compared to those without evidence
of infection. Finally we hypothesised that glial cell death associated with
actively demyelinating plaques would result in release of astrocytic pro-
teins such as S100B and glial ﬁbrillary acidic protein (GFAP)7 and would
thus be elevated in those patients who were MSRV positive.
Plasma samples were available from eighteen patients with acute optic
neuritis (ON) from a previously reported cohort.8
2Ten patients had baseline MRI scans and 7 had follow–up MRI scans,
the remainder had no clinical relapses during the follow up period. The
control group consisted of 17 patients with other non–inﬂammatory neuro-
logical diseases. Isoelectric focusing for detection of intrathecal IgG was
performed in all of the control patients and none had oligoclonal bands.
Blood samples were collected, spun down and stored in 2 mL aliquots
at -70◦C. Coded samples were analysed for presence of MSRV as de-
scribed.9 The previously deﬁned cut-off for a positive test was an optical
density (OD) above 0.8. Plasma S100B and GFAP were measured us-
ing standard ELISA systems with a sensitivity of 0.04 ng/mL and 5 pg/mL,
respectively.10,11 Statistical analysis was performed using Fisher’s exact
test for categorical variables and the non–parametric Kruskal-Wallis test
for continuous variables.
The patients were younger (median 32 years, range 30–41) compared
to the control population (51, 37–61), but there was no difference in age
between those who developed clinically–deﬁnite MS according to the Poser
criteria (CDMS) (27, 32-31) and those who did not (33, 31-41). The me-
dian follow–up time was 12 months (range 5–42). As reported previously,8
only 2 patients developed CDMS. In another 2 patients the MRI showed
new lesions separated in time and space, thus satisfying the MacDonald
criteria.12 However, none of the patients had evidence of MSRV infection,
unlike two of the controls. There was no difference in the median OD,
between either the Poser–positive or MacDonald–positive patients.
3The glial proteins S100B and GFAP were not found to be elevated in
the plasma of these patients. This may in part be related to the assays’
sensitivity.
In contrast to the Sardinian cohort and cell lines from previously re-
ported cohorts, this study investigated for the ﬁrst time the presence of
MSRV in patients with acute ON.1,2,5 The working hypothesis that some
patients with ON might have been MSRV carriers with active virion recir-
culation (viraemia) and have a higher risk of developing MS could not be
proven. Interestingly the Sardinian group described infection with MSRV
also in a signiﬁcantly higher proportion of patients with other inﬂammatory
diseases (63.6%) when compared to healthy blood donors (12.8%).5 We
agree with these authors that infection with MSRV might merely represent
an epiphenomenon,5 but the very particular type of retroviral agent, be-
longing to a family of endogenous human retroviruses, HERV-W, raises
much more complex questions.13
The fact that ON patients did not have negative viraemia on their ﬁrst
symptomatic manifestation, does not preclude them from carrying the MSRV
genome in their cells: it may be that it was not expressed prior to and dur-
ing the onset phase of ON. Further studies should therefore be extended to
patients who went on to develop MS, to investigate whether they then had
an MSRV viraemia. Such a study has the potential to provide a valuable
insight into the possibility that ON could be caused by another infectious
agent or environmental factor, which triggers MSRV reactivation in sus-
4ceptible carriers, as suggested by experimental data on MSRV transacti-
vation.14 Whether this could be a condition for the late evolution towards
MS in such cases would also require follow–up studies with controls who
have not developed MS after acute ON.
This study cannot however contribute to the question of whether MSRV
might additionally contribute to gliotoxicity since none of the ON patients
had MSRV viraemia.
Acknowledgement The NMR Research Unit is supported by The Mul-
tiple Sclerosis Society of Great Britain and Northern Ireland. KF is sup-
ported by Biogen.
References
[1] H Perron, C Geny, A Laurent, et al. Leptomeningeal cell line from
multiple sclerosis with reverse transcriptase activity and viral parti-
cles. Research in Virology, 140:551–561, 1989.
[2] H Perron, JA Garson, F Bedin, et al. Molecular identiﬁcation of a
novel retrovirus repeatedly isolated from patients with multiple scle-
rosis. The Collaborative Research Group on Multiple Sclerosis. Proc
Natl Acad Sci U S A, 94:7583–7508, 1997.
[3] P Rudge. Does a retrovirally encoded superantigen cause multiple
sclerosis? J Neurol Neurosurg Psychiatry, 54:853–805, 1991.
5[4] A Menard, R Amouri, M Michel, et al. Gliotoxicity, reverse transcrip-
tase activity and retroviral RNA in monocyte/macrophage culture su-
pernatants from patients with multiple sclerosis. FEBS Lett, 413:477–
485, 1997.
[5] A Dolei, C Serra, G Mameli, et al. Multiple sclerosis-associated
retrovirus (MSRV) in Sardinian MS patients. Neurology, 58:471–473,
2002.
[6] S Sotgiu, C Serra, G Mameli, et al. Multiple Sclerosis-associated
retrovirus and MS prognosis: an observational study. Neurology,
59:1071–1073, 2002.
[7] A Petzold, MJ Eikelenboom, D Gveric, G Keir, M Chapman, RH Laze-
ron, et al. Markers for different glial cell responses in multiple scle-
rosis: Clinical and pathological correlations. Brain, 125:1462–1473,
2002.
[8] A Petzold, K Rejdak, and GT Plant. Axonal degeneration and in-
ﬂammation in acute optic neuritis. J Neurol Neurosurg Psychiatry,
75:1178–1180, 2004.
[9] JA Garson, PW Tuke, P Giraud, G Paranhos-Baccala, and H Perron.
Detection of virion-associated MSRV-RNA in serum of patients with
multiple sclerosis. The Lancet, 351:33, 1998.
6[10] AJE Green, G Keir, and EJ Thompson. A speciﬁc and sensitive ELISA
for measuring S-100b in cerebrospinal ﬂuid. J Immunol Meth, 205:35–
41, 1997.
[11] A Petzold, G Keir, Green AJE, G Giovannoni, and EJ Thompson. An
ELISA for glial ﬁbrillary acidic protein. J Immunol Meth, 287:169–177,
2004.
[12] WI McDonald, A Compston, G Edan, et al. Recommended diagnostic
criteria for multiple sclerosis: guidelines from the International Panel
on the diagnosis of multiple sclerosis. Ann Neurol, 50:121–127, 2001.
[13] H Perron, JP Perin, F Rieger, and PM Alliel. Particle-associated retro-
viral RNA and tandem RGH/HERV-W copies on human chromosome
7q: possible components of a ’chain-reaction’ triggered by infectious
agents in multiple sclerosis? J Neurovirol, 6 Suppl 2:S67–75, 2000.
[14] H Perron, M Suh, B Lalande, B Gratacap, A Laurent, P Stoebner, and
JM Seigneurin. Herpes simplex virus ICP0 and ICP4 immediate early
proteins strongly enhance expression of a retrovirus harboured by a
leptomeningeal cell line from a patient with multiple sclerosis. J Gen
Virol, 74:65–72, 1993.T
a
b
l
e
1
:
C
h
a
r
a
c
t
e
r
i
s
t
i
c
s
o
f
p
a
t
i
e
n
t
s
e
x
p
r
e
s
s
e
d
a
s
m
e
d
i
a
n
s
(
i
n
-
t
e
r
q
u
a
r
t
i
l
e
r
a
n
g
e
)
.
’
N
D
’
=
n
o
n
d
e
t
e
c
t
a
b
l
e
,
’
N
/
A
’
=
n
o
t
a
v
a
i
l
a
b
l
e
,
’
N
.
S
.
’
=
n
o
t
s
i
g
n
i
ﬁ
c
a
n
t
,
’
C
D
M
S
+
’
d
e
s
c
r
i
b
e
s
t
h
o
s
e
p
a
t
i
e
n
t
s
w
i
t
h
c
l
i
n
i
c
a
l
d
e
ﬁ
n
i
t
e
M
S
a
c
c
o
r
d
i
n
g
t
o
t
h
e
P
o
s
e
r
c
r
i
t
e
r
i
a
a
n
d
’
C
D
M
S
-
’
t
h
o
s
e
w
i
t
h
o
u
t
.
L
e
v
e
l
s
o
f
s
i
g
n
i
ﬁ
c
a
n
c
e
a
r
e
p
r
e
s
e
n
t
e
d
c
o
m
p
a
r
i
n
g
C
o
n
t
r
o
l
w
i
t
h
O
N
p
a
t
i
e
n
t
s
a
n
d
C
D
M
S
-
w
i
t
h
C
D
M
S
+
p
a
t
i
e
n
t
s
.
F
e
a
t
u
r
e
C
o
n
t
r
o
l
s
O
N
C
D
M
S
-
C
D
M
S
+
S
i
g
n
i
ﬁ
c
a
n
c
e
A
g
e
(
y
e
a
r
s
)
5
1
(
3
7
–
6
1
)
3
2
(
3
0
–
4
1
)
3
3
(
3
1
–
4
1
)
2
7
(
2
3
–
3
1
)
p
<
0
.
0
1
,
N
.
S
.
F
e
m
a
l
e
/
m
a
l
e
8
/
9
9
/
5
5
/
7
2
/
0
N
.
S
.
N
.
S
.
F
o
l
l
o
w
–
u
p
(
m
o
n
t
h
s
)
N
/
A
1
2
(
5
–
4
2
)
9
(
4
–
4
0
)
3
6
(
3
0
–
4
2
)
N
/
A
,
N
.
S
.
M
R
I
p
o
s
i
t
i
v
e
N
/
A
4
/
1
0
(
4
0
%
)
2
/
8
(
2
5
%
)
2
/
2
(
1
0
0
%
)
N
/
A
,
N
.
S
.
M
S
R
V
(
O
D
)
0
.
3
1
(
0
.
2
4
–
0
.
5
1
)
0
.
2
6
(
0
.
2
0
–
0
.
4
0
)
0
.
2
4
(
0
.
2
0
–
0
.
4
0
)
0
.
3
1
a
n
d
0
.
6
8
N
.
S
.
N
.
S
.
M
S
R
V
p
o
s
i
t
i
v
e
2
/
1
7
(
1
2
%
)
0
/
1
4
(
0
%
)
0
/
1
6
(
0
%
)
0
/
2
(
0
%
)
N
.
S
.
N
.
S
.
P
l
a
s
m
a
S
1
0
0
B
[
n
g
/
m
L
]
a
N
D
0
(
0
–
0
.
0
0
8
)
0
.
0
0
(
0
–
0
.
0
0
8
)
0
.
0
0
a
n
d
0
.
0
0
8
N
.
S
.
N
.
S
.
P
l
a
s
m
a
G
F
A
P
[
n
g
/
m
L
]
N
D
N
D
N
D
N
D
N
.
S
.
N
.
S
.
N
u
m
b
e
r
1
7
1
4
1
2
2
a
T
h
e
m
e
d
i
a
n
a
n
d
r
a
n
g
e
i
s
g
i
v
e
n